Unlocking The Potential of Dipeptidase 2 as A Drug and Biomarker
Unlocking The Potential of Dipeptidase 2 as A Drug and Biomarker
Dipeptidase 2 (DPEP2), also known as transcript variant 1, is a protein that is expressed in various tissues throughout the body. It is a member of the family of enzymes known as dipeptidases and is involved in the breakdown of dipeptides, which are short chains of amino acids.
One of the unique features of DPEP2 is its ability to catalyze the hydrolysis of specific dipeptides, such as alanine-content peptides. This hydrolysis reaction is critical for the proper functioning of many cellular processes, including the regulation of ion channels, the transport of nutrients and oxygen, and the degradation of damaged or unnecessary proteins.
DPEP2 has also been shown to play a key role in the regulation of cellular signaling pathways. In particular, it has been shown to interact with the protein known as Pyruvate Carrier Proteins (PCP), which are involved in the transport of pyruvate, a critical carbon source, to the cytosol of cells.
These interactions between DPEP2 and PCP have important implications for the regulation of cellular metabolism and signaling. They may also be potential drug targets or biomarkers for the treatment of various diseases.
One of the most promising aspects of DPEP2 is its potential as a drug target. Thebecause it is involved in the regulation of cellular signaling pathways, it may be a useful target for the treatment of various diseases that are caused by the disruption of these signaling pathways.
For example, DPEP2 has been shown to be involved in the regulation of the growth and differentiation of cancer cells. In particular, it has been shown to play a key role in the regulation of the angiogenesis, which is the process by which cancer cells develop blood vessels to supply them with oxygen and nutrients.
Another potential application of DPEP2 as a drug target is its role in the regulation of the immune response. DPEP2 has been shown to interact with the protein known as PD-L1, which is involved in the regulation of immune cell function.
These interactions between DPEP2 and PD-L1 have important implications for the regulation of the immune response and the development of cancer. They may also be potential biomarkers for the diagnosis and treatment of various immunodeficiency diseases.
In addition to its potential as a drug target or biomarker, DPEP2 is also a potential biomarker for the diagnosis of certain diseases. For example, it has been shown to be involved in the regulation of the metabolism of certain neurotransmitters, such as dopamine and serotonin.
The regulation of neurotransmitter metabolism is critical for the function of many brain cells and is implicated in the development of various neurological disorders. DPEP2's involvement in this process may make it a useful biomarker for the diagnosis and treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
In conclusion, Dipeptidase 2 (DPEP2) is a protein that is involved in the breakdown of dipeptides and the regulation of cellular signaling pathways. Its unique ability to catalyze the hydrolysis of specific dipeptides makes it a potential drug target and a useful biomarker for the diagnosis and treatment of various diseases. Further research is needed to fully understand the role of DPEP2 in cellular processes and its potential as a drug and biomarker.
Protein Name: Dipeptidase 2
Functions: Dipeptidase that hydrolyzes leukotriene D4 (LTD4) into leukotriene E4 (LTE4) (PubMed:32325220). Hydrolyzes cystinyl-bis-glycine (PubMed:32325220)
The "DPEP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPEP2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
DPEP3 | DPF1 | DPF2 | DPF3 | DPH1 | DPH2 | DPH3 | DPH3P1 | DPH5 | DPH5-DT | DPH6 | DPH6-DT | DPH7 | DPM1 | DPM2 | DPM3 | DPP10 | DPP10-AS1 | DPP3 | DPP3-DT | DPP4 | DPP6 | DPP7 | DPP8 | DPP9 | DPP9-AS1 | DPPA2 | DPPA2P3 | DPPA3 | DPPA3P1 | DPPA3P2 | DPPA4 | DPPA4P3 | DPPA5 | DPPA5P4 | DPRX | DPRXP2 | DPRXP4 | DPT | DPY19L1 | DPY19L1P1 | DPY19L2 | DPY19L2P1 | DPY19L2P2 | DPY19L2P3 | DPY19L2P4 | DPY19L3 | DPY19L3-DT | DPY19L4 | DPY30 | DPYD | DPYD-AS1 | DPYS | DPYSL2 | DPYSL3 | DPYSL4 | DPYSL5 | DQX1 | DR1 | DRAIC | DRAM1 | DRAM2 | DRAP1 | DRAXIN | DRB sensitivity-inducing factor complex | DRC1 | DRC3 | DRC7 | DRD1 | DRD2 | DRD3 | DRD4 | DRD5 | DRD5P1 | DRD5P2 | DRG1 | DRG2 | DRGX | DRICH1 | DROSHA | DRP2 | DSC1 | DSC2 | DSC3 | DSCAM | DSCAM-AS1 | DSCAML1 | DSCC1 | DSCR10 | DSCR4 | DSCR8 | DSCR9 | DSE | DSEL | DSEL-AS1 | DSG1 | DSG1-AS1 | DSG2 | DSG3 | DSG4
